Overview of the global nanoparticles market in biotechnology and pharmaceutical sectors
The nanoparticle segment of the nanotechnology has wider application in pharmaceuticals such as in drug delivery and drug discovery, and in biotechnology such as in studying cellular dynamics and stem cell research. Nanotechnology is growing steadily supported by governments and technology firms making high investments in developing nanotechnology. Technavio’s market study identifies the increasing focus on nanotechnology research to be one of the primary growth factors for the nanoparticles market in biotechnology and pharmaceutical sectors. Consequently, the increased emphasis on nanotechnology research in the nanotechnology market has influenced the number of nanoparticle-based products under clinical trials. Our market analysts estimate that the market will grow steadily at a CAGR of around 22% by 2021.
Sedentary lifestyles and unbalanced diets, supported by the growing rate of urbanization, are consequent in increased widespread prevalence of chronic diseases. Chronic and lifestyle diseases such as cancer, heart diseases, stroke, chronic respiratory diseases, and diabetes. Nanoparticles are utilized to determine the biological alterations of peptide and protein fragments. This diagnosis aids in developing new treatment solutions to treat the growing incidences of chronic diseases. The increasing prevalence of chronic diseases is identified to be one of the key trends having a positive impact on the nanoparticles market in biotechnology and pharmaceutical sectors.
Competitive landscape and key vendors
The nanoparticles market in biotechnology and pharmaceutical sectors is significantly fragmented owing to the presence of several international and regional players. International players dominate the competition in terms of quality, price, market reach, and financial resources. Increase in product innovations, product and service extensions, and M&A will further intensify the competition among the vendors. This will encourage the vendors to develop innovative products. High growth potential of the nanotechnology market boosts the entry of several new players.
The leading vendors in the market are
- F. Hoffmann-La Roche
- GE Healthcare
- Merck
- Novartis
The other prominent vendors in the market are AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire, and UCB.
Segmentation by end-user and analysis of the nanoparticles market in biotechnology and pharmaceutical sectors
- Biotechnology
- Pharmaceutical
The biotechnology segment accounts for major market share in the nanoparticles market in biotechnology and pharmaceutical sectors due to the application of nanoparticles in genetic controlling of cells and labelling and studying cellular dynamics. Increased demand for food and drugs is influencing increased R&D in biotechnology. This demand further influences the implementation of cutting-edge technologies such as nanotechnology to develop advanced products at reasonable costs.
Geographical segmentation and analysis of the nanoparticles market in biotechnology and pharmaceutical sectors
The Americas will be the major revenue contributor to the nanotechnology market owing to the availability of superior healthcare infrastructure that implements nanotechnology for its wide application areas. Additionally, the increasing awareness of the importance of diagnostics in personalized medicine and initiatives undertaken by the government to promote the use of personalized medicine will further contribute to the growth of the market. Also, this region is witnessing high prevalence of diseases that require nanoparticles in research and therapy.
Key questions answered in the report include
- What will the market size and the growth rate be in 2021?
- What are the key factors driving the global nanoparticles market in biotechnology and pharmaceutical sectors?
- What are the key market trends impacting the growth of the global nanoparticles market in biotechnology and pharmaceutical sectors?
- What are the challenges to market growth?
- Who are the key vendors in the global nanoparticles market in biotechnology and pharmaceutical sectors?
- What are the market opportunities and threats faced by the vendors in the global nanoparticles market in biotechnology and pharmaceutical sectors?
- Trending factors influencing the market shares of the Americas, APAC, and EMEA.
- What are the key outcomes of the five forces analysis of the global nanoparticles market in biotechnology and pharmaceutical sectors?
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MARKET LANDSCAPE
- Market size and forecast
- Five forces analysis
PART 06: MARKET SEGMENTATION BY END-USER
- Comparison by end-user
- Biotechnology
- Pharmaceutical
- Market opportunity by end-user
PART 07: REGIONAL LANDSCAPE
- Regional comparison
- Nanoparticles market in biotechnology and pharmaceutical sectors in Americas
- Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA
- Nanoparticles market in biotechnology and pharmaceutical sectors in APAC
- Market opportunity
PART 08: DECISION FRAMEWORK
PART 09: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 10: MARKET TRENDS
- Increasing demand for nanoparticles in stem cell therapy
- Increasing prevalence of chronic diseases
- Increasing use of gold nanoparticles
PART 11: VENDOR LANDSCAPE
- Competitive scenario
- Investment opportunity
PART 12: VENDOR ANALYSIS
- Vendor overview
- Merck
- F. Hoffmann-La Roche
- GE Healthcare
- Novartis
- Other prominent vendors
PART 13: APPENDIX